Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer.

Verlaat W, Van Leeuwen RW, Novianti PW, Schuuring E, Meijer CJLM, Van Der Zee AGJ, Snijders PJF, Heideman DAM, Steenbergen RDM, Wisman GBA.

Epigenetics. 2018 Aug 24:1-10. doi: 10.1080/15592294.2018.1507197. [Epub ahead of print]

PMID:
30079796
2.

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.

Caumanns JJ, Wisman GBA, Berns K, van der Zee AGJ, de Jong S.

Biochim Biophys Acta. 2018 Jul 16. pii: S0304-419X(18)30091-X. doi: 10.1016/j.bbcan.2018.07.005. [Epub ahead of print] Review.

3.

HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in situ hybridization.

Koopman T, van der Vegt B, Dijkstra M, Bart J, Duiker E, Wisman GBA, de Bock GH, Hollema H.

Histopathology. 2018 Jul 10. doi: 10.1111/his.13704. [Epub ahead of print]

PMID:
29989198
4.

Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1.

Maldonado L, Brait M, Izumchenko E, Begum S, Chatterjee A, Sen T, Loyo M, Barbosa A, Poeta ML, Makarev E, Zhavoronkov A, Fazio VM, Angioli R, Rabitti C, Ongenaert M, Van Criekinge W, Noordhuis MG, de Graeff P, Wisman GBA, van der Zee AGJ, Hoque MO.

Cancer Lett. 2018 Oct 1;433:242-251. doi: 10.1016/j.canlet.2018.06.030. Epub 2018 Jun 28.

PMID:
29964205
5.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.

Oncogene. 2018 May 15. doi: 10.1038/s41388-018-0300-6. [Epub ahead of print]

6.

Proteomic alterations in early stage cervical cancer.

Güzel C, Govorukhina NI, Wisman GBA, Stingl C, Dekker LJM, Klip HG, Hollema H, Guryev V, Horvatovich PL, van der Zee AGJ, Bischoff R, Luider TM.

Oncotarget. 2018 Apr 6;9(26):18128-18147. doi: 10.18632/oncotarget.24773. eCollection 2018 Apr 6.

7.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S.

Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23.

PMID:
29685880
8.

A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.

Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Joehrens K, Vergote I, Vanderstichele A, Boeckx B, Lambrechts D, Gabra H, Wisman GBA, Trillsch F, Heinze G, Horvat R, Polterauer S, Berns E, Theillet C, Cacsire Castillo-Tong D.

Clin Cancer Res. 2017 Dec 15;23(24):7621-7632. doi: 10.1158/1078-0432.CCR-17-1159. Epub 2017 Oct 2.

PMID:
28972047
9.

CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer.

Komdeur FL, Prins TM, van de Wall S, Plat A, Wisman GBA, Hollema H, Daemen T, Church DN, de Bruyn M, Nijman HW.

Oncoimmunology. 2017 Jul 24;6(9):e1338230. doi: 10.1080/2162402X.2017.1338230. eCollection 2017.

10.

Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker.

Corvigno S, Frödin M, Wisman GBA, Nijman HW, Van der Zee AG, Jirström K, Nodin B, Hrynchyk I, Edler D, Ragnhammar P, Johansson M, Dahlstrand H, Mezheyeuski A, Östman A.

J Pathol Clin Res. 2017 Jul 24;3(3):214-224. doi: 10.1002/cjp2.74. eCollection 2017 Jul.

11.

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.

Tomar T, Alkema NG, Schreuder L, Meersma GJ, de Meyer T, van Criekinge W, Klip HG, Fiegl H, van Nieuwenhuysen E, Vergote I, Widschwendter M, Schuuring E, van der Zee AGJ, de Jong S, Wisman GBA.

BMC Med. 2017 Jun 23;15(1):116. doi: 10.1186/s12916-017-0870-0.

12.

Genome-wide DNA Methylation Profiling Reveals Methylation Markers Associated with 3q Gain for Detection of Cervical Precancer and Cancer.

Verlaat W, Snijders PJF, Novianti PW, Wilting SM, De Strooper LMA, Trooskens G, Vandersmissen J, Van Criekinge W, Wisman GBA, Meijer CJLM, Heideman DAM, Steenbergen RDM.

Clin Cancer Res. 2017 Jul 15;23(14):3813-3822. doi: 10.1158/1078-0432.CCR-16-2641. Epub 2017 Jan 24.

13.

Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.

Fedoseienko A, Wieringa HW, Wisman GB, Duiker E, Reyners AK, Hofker MH, van der Zee AG, van de Sluis B, van Vugt MA.

PLoS One. 2016 Oct 27;11(10):e0165385. doi: 10.1371/journal.pone.0165385. eCollection 2016.

14.
15.

Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adeno- and squamous-cell cervical carcinoma.

Wang R, van Leeuwen RW, Boers A, Klip HG, de Meyer T, Steenbergen RD, van Criekinge W, van der Zee AG, Schuuring E, Wisman GB.

Oncotarget. 2016 Dec 6;7(49):80735-80750. doi: 10.18632/oncotarget.12598.

16.

Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.

Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A, Cunnea P, Gabra H, Braicu EI, Sehouli J, Darb-Esfahani S, Vanderstichele A, Vergote I, Kreuzinger C, Castillo-Tong DC, Wisman GBA, Berns EM, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2017 May 1;23(9):2213-2222. doi: 10.1158/1078-0432.CCR-16-1754. Epub 2016 Sep 23.

17.

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.

Komdeur FL, Wouters MC, Workel HH, Tijans AM, Terwindt AL, Brunekreeft KL, Plat A, Klip HG, Eggink FA, Leffers N, Helfrich W, Samplonius DF, Bremer E, Wisman GB, Daemen T, Duiker EW, Hollema H, Nijman HW, de Bruyn M.

Oncotarget. 2016 Nov 15;7(46):75130-75144. doi: 10.18632/oncotarget.12077.

18.

RAB25 expression is epigenetically downregulated in oral and oropharyngeal squamous cell carcinoma with lymph node metastasis.

Clausen MJ, Melchers LJ, Mastik MF, Slagter-Menkema L, Groen HJ, Laan BF, van Criekinge W, de Meyer T, Denil S, van der Vegt B, Wisman GB, Roodenburg JL, Schuuring E.

Epigenetics. 2016 Sep;11(9):653-663. Epub 2016 Jul 5.

19.

CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.

Workel HH, Komdeur FL, Wouters MC, Plat A, Klip HG, Eggink FA, Wisman GB, Arts HJ, Oonk MH, Mourits MJ, Yigit R, Versluis M, Duiker EW, Hollema H, de Bruyn M, Nijman HW.

Eur J Cancer. 2016 Jun;60:1-11. doi: 10.1016/j.ejca.2016.02.026. Epub 2016 Mar 31.

PMID:
27038842
20.

Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3.

Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, van Criekinge W, de Meyer T, Denil S, van der Zee AGJ, Schuuring E, Wisman GBA.

Clin Epigenetics. 2016 Mar 9;8:29. doi: 10.1186/s13148-016-0196-3. eCollection 2016.

21.

Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival.

Corvigno S, Wisman GB, Mezheyeuski A, van der Zee AG, Nijman HW, Åvall-Lundqvist E, Östman A, Dahlstrand H.

Oncotarget. 2016 Apr 5;7(14):18573-84. doi: 10.18632/oncotarget.7613.

22.

Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.

Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S.

Drug Resist Updat. 2016 Jan;24:55-69. doi: 10.1016/j.drup.2015.11.005. Epub 2015 Nov 26. Review.

PMID:
26830315
23.

Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation.

Huisman C, van der Wijst MG, Schokker M, Blancafort P, Terpstra MM, Kok K, van der Zee AG, Schuuring E, Wisman GB, Rots MG.

Mol Ther. 2016 Mar;24(3):536-47. doi: 10.1038/mt.2015.226. Epub 2015 Dec 21.

24.

HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.

Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S, Vergote I, Calvert H, Jacobs IJ, Widschwendter M.

Genome Med. 2015 Oct 24;7:108. doi: 10.1186/s13073-015-0233-4.

25.

Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods.

Alkema NG, Tomar T, Duiker EW, Jan Meersma G, Klip H, van der Zee AG, Wisman GB, de Jong S.

Sci Rep. 2015 Oct 6;5:14495. doi: 10.1038/srep14495.

26.

Identification and validation of WISP1 as an epigenetic regulator of metastasis in oral squamous cell carcinoma.

Clausen MJ, Melchers LJ, Mastik MF, Slagter-Menkema L, Groen HJ, van der Laan BF, van Criekinge W, de Meyer T, Denil S, Wisman GB, Roodenburg JL, Schuuring E.

Genes Chromosomes Cancer. 2016 Jan;55(1):45-59. doi: 10.1002/gcc.22310. Epub 2015 Sep 22.

PMID:
26391330
27.

Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.

Wouters MC, Komdeur FL, Workel HH, Klip HG, Plat A, Kooi NM, Wisman GB, Mourits MJ, Arts HJ, Oonk MH, Yigit R, de Jong S, Melief CJ, Hollema H, Duiker EW, Daemen T, de Bruyn M, Nijman HW.

Clin Cancer Res. 2016 Feb 1;22(3):714-24. doi: 10.1158/1078-0432.CCR-15-1617. Epub 2015 Sep 18.

28.

Identification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinoma.

Melchers LJ, Clausen MJ, Mastik MF, Slagter-Menkema L, van der Wal JE, Wisman GB, Roodenburg JL, Schuuring E.

Epigenetics. 2015;10(9):850-60. doi: 10.1080/15592294.2015.1075689.

29.

Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China.

Wang R, Guo XL, Wisman GB, Schuuring E, Wang WF, Zeng ZY, Zhu H, Wu SW.

BMC Infect Dis. 2015 Jul 4;15:257. doi: 10.1186/s12879-015-0998-5.

30.

Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs.

Huisman C, van der Wijst MG, Falahi F, Overkamp J, Karsten G, Terpstra MM, Kok K, van der Zee AG, Schuuring E, Wisman GB, Rots MG.

Epigenetics. 2015;10(5):384-96. doi: 10.1080/15592294.2015.1034415. Epub 2015 Apr 1.

31.

Mining for viral fragments in methylation enriched sequencing data.

Mensaert K, Van Criekinge W, Thas O, Schuuring E, Steenbergen RD, Wisman GB, De Meyer T.

Front Genet. 2015 Feb 4;6:16. doi: 10.3389/fgene.2015.00016. eCollection 2015.

32.

Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening.

Boers A, Wang R, Slagter-Menkema L, van Hemel BM, Ghyssaert H, van der Zee AG, Wisman GB, Schuuring E.

J Clin Microbiol. 2014 Dec;52(12):4391-3. doi: 10.1128/JCM.02716-14. Epub 2014 Oct 8.

33.

CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer.

De Strooper LM, van Zummeren M, Steenbergen RD, Bleeker MC, Hesselink AT, Wisman GB, Snijders PJ, Heideman DA, Meijer CJ.

J Clin Pathol. 2014 Dec;67(12):1067-71. doi: 10.1136/jclinpath-2014-202616. Epub 2014 Oct 3.

PMID:
25281766
34.

Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off.

Boers A, Slagter-Menkema L, van Hemel BM, Belinson JL, Ruitenbeek T, Buikema HJ, Klip H, Ghyssaert H, van der Zee AG, de Bock GH, Wisman GB, Schuuring E.

PLoS One. 2014 Jul 22;9(7):e101930. doi: 10.1371/journal.pone.0101930. eCollection 2014.

35.

DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women.

Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DA, Massuger LF, Verhoef VM, Bulten J, Melchers WJ, van der Zee AG, Bekkers RL, Wisman GB.

Br J Cancer. 2014 Sep 9;111(6):1095-101. doi: 10.1038/bjc.2014.392. Epub 2014 Jul 17.

36.

Radical surgery in patients with residual disease after (chemo)radiation for cervical cancer.

Boers A, Arts HJ, Klip H, Nijhuis ER, Pras E, Hollema H, Wisman GB, Nijman HW, Mourits MJ, Reyners AK, de Bock GH, Thomas G, van der Zee AG.

Int J Gynecol Cancer. 2014 Sep;24(7):1276-85. doi: 10.1097/IGC.0000000000000171.

PMID:
24987914
37.

Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.

Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.

Gynecol Oncol. 2014 Jun;133(3):591-8. doi: 10.1016/j.ygyno.2014.03.557. Epub 2014 Mar 20.

PMID:
24657486
38.

Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression.

Brait M, Maldonado L, Noordhuis MG, Begum S, Loyo M, Poeta ML, Barbosa A, Fazio VM, Angioli R, Rabitti C, Marchionni L, de Graeff P, van der Zee AG, Wisman GB, Sidransky D, Hoque MO.

PLoS One. 2013 Sep 27;8(9):e70878. doi: 10.1371/journal.pone.0070878. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/ccd51e37-fdf3-466e-b79f-2c390df9ab28. PLoS One. 2013;8(10). doi:10.1371/annotation/5d2e13d4-cb4e-44b1-a836-dff9b4144b5b. Noordhuis, Maartje [corrected to Noordhuis, Maartje G].

39.

Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors.

Huisman C, Wisman GB, Kazemier HG, van Vugt MA, van der Zee AG, Schuuring E, Rots MG.

Mol Oncol. 2013 Jun;7(3):669-79. doi: 10.1016/j.molonc.2013.02.017. Epub 2013 Mar 5.

40.

CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease.

Bierkens M, Hesselink AT, Meijer CJ, Heideman DA, Wisman GB, van der Zee AG, Snijders PJ, Steenbergen RD.

Int J Cancer. 2013 Sep 15;133(6):1293-9. doi: 10.1002/ijc.28138. Epub 2013 Apr 4.

41.

Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia.

Lendvai Á, Johannes F, Grimm C, Eijsink JJ, Wardenaar R, Volders HH, Klip HG, Hollema H, Jansen RC, Schuuring E, Wisman GB, van der Zee AG.

Epigenetics. 2012 Nov;7(11):1268-78. doi: 10.4161/epi.22301. Epub 2012 Sep 27.

42.

DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art.

Roossink F, de Jong S, Wisman GB, van der Zee AG, Schuuring E.

Cell Oncol (Dordr). 2012 Aug;35(4):231-41. doi: 10.1007/s13402-012-0091-7. Epub 2012 Jul 27. Review.

PMID:
22836879
43.

The role of ATM and 53BP1 as predictive markers in cervical cancer.

Roossink F, Wieringa HW, Noordhuis MG, ten Hoor KA, Kok M, Slagter-Menkema L, Hollema H, de Bock GH, Pras E, de Vries EG, de Jong S, van der Zee AG, Schuuring E, Wisman GB, van Vugt MA.

Int J Cancer. 2012 Nov 1;131(9):2056-66. doi: 10.1002/ijc.27488. Epub 2012 Mar 29.

44.

Identification of inguinofemoral lymph node metastases by methylation markers in vulvar cancer.

Oonk MH, Eijsink JJ, Volders HH, Hollema H, Wisman GB, Schuuring E, van der Zee AG.

Gynecol Oncol. 2012 May;125(2):352-7. doi: 10.1016/j.ygyno.2012.01.013. Epub 2012 Jan 18.

PMID:
22266550
45.

A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients.

Eijsink JJ, Lendvai Á, Deregowski V, Klip HG, Verpooten G, Dehaspe L, de Bock GH, Hollema H, van Criekinge W, Schuuring E, van der Zee AG, Wisman GB.

Int J Cancer. 2012 Apr 15;130(8):1861-9. doi: 10.1002/ijc.26326. Epub 2012 Feb 13.

46.

Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer.

Noordhuis MG, Fehrmann RS, Wisman GB, Nijhuis ER, van Zanden JJ, Moerland PD, Ver Loren van Themaat E, Volders HH, Kok M, ten Hoor KA, Hollema H, de Vries EG, de Bock GH, van der Zee AG, Schuuring E.

Clin Cancer Res. 2011 Mar 15;17(6):1317-30. doi: 10.1158/1078-0432.CCR-10-2320. Epub 2011 Mar 8.

47.

Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review.

Noordhuis MG, Eijsink JJ, Roossink F, de Graeff P, Pras E, Schuuring E, Wisman GB, de Bock GH, van der Zee AG.

Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):325-34. doi: 10.1016/j.ijrobp.2010.09.043. Review.

PMID:
21195874
48.

Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors.

Bijsmans IT, Smits KM, de Graeff P, Wisman GB, van der Zee AG, Slangen BF, de Bruïne AP, van Engeland M, Sieben NL, Van de Vijver KK.

Mod Pathol. 2011 Mar;24(3):463-70. doi: 10.1038/modpathol.2010.214. Epub 2010 Nov 19.

49.

Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study.

Eijsink JJ, Yang N, Lendvai A, Klip HG, Volders HH, Buikema HJ, van Hemel BM, Voll M, Coelingh Bennink HJ, Schuuring E, Wisman GB, van der Zee AG.

Gynecol Oncol. 2011 Feb;120(2):280-3. doi: 10.1016/j.ygyno.2010.10.029. Epub 2010 Nov 19.

50.

The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer.

Eijsink JJ, Noordhuis MG, ten Hoor KA, Kok M, Hollema H, de Bock GH, Nijman HW, Schuuring E, Wisman GB, van der Zee AG.

Hum Pathol. 2010 Dec;41(12):1735-41. doi: 10.1016/j.humpath.2010.04.017.

PMID:
21078436

Supplemental Content

Loading ...
Support Center